NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. In cellular settings using human tumor cell lines, this molecule is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest at IC50 values of 3-10nM in biological cell growth and viability assays. In addition NVP-BEZ235 shows effective IC50 values in in vitro tests against mTOR and PI3K family members of 10nM.
Product Specification
| Alternative Name: | NVP-BEZ235, Dactolisib, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile |
| |
| Formula: | C30H23N5O |
| |
| MW: | 469.5 |
| |
| CAS: | 915019-65-7 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in DMSO (1mg/ml) or ethanol (1mg/ml). |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
